Partial suppression of CETP activity beneficially modifies the lipid transfer profile of plasma


      Cholesteryl ester transfer protein (CETP) regulates human lipoprotein metabolism. Because reducing CETP increases plasma HDL, CETP inhibitors are currently being investigated for their pharmacologic value. However, complete CETP deficiency may have undesirable consequences. In contrast, based on previous studies with purified components, we hypothesized that partial CETP inhibition, which will still elevate HDL, may induce beneficial changes in plasma lipid metabolism. To address this, CETP activity in human plasma was variably inhibited with monoclonal antibody. In control plasma, VLDL to LDL lipid transfer was >2-fold higher than to HDL3 with lipid transfer to HDL2 intermediate. However, individual lipid transfer events were uniquely sensitive to CETP suppression such that when CETP activity was inhibited by 60%, lipid transfer from VLDL to LDL, HDL2 and HDL3 were equal. The ratio of lipid transfers to LDL versus HDL declined linearly with CETP inhibition. In mass lipid transfer experiments, 25–50% inhibition of CETP significantly reduced lipid flux between VLDL and LDL but minimally affected cholesteryl ester (CE) loss from HDL. Complete CETP inhibition did not reduce cholesterol esterification rates but completely blocked the delivery of new CE to VLDL, whereas, 50% inhibition of CETP reduced this CE flux to VLDL by <20%. Thus, inhibition of CETP by ≤50% preferentially blocks lipid transfers involving LDL while largely maintaining lipid flux through HDL. These results suggest that a more beneficial therapeutic outcome may be achieved with partial, rather than extensive, CETP suppression.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Morton R.E.
        Interaction of lipid transfer protein with plasma lipoproteins and cell membranes.
        Experientia. 1990; 46: 552-560
        • Tall A.
        Plasma lipid transfer proteins.
        Annu Rev Biochem. 1995; 64: 235-257
        • Barter P.J.
        • Brewer Jr., H.B.
        • Chapman M.J.
        • et al.
        Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
        Arterioscler Thromb Vasc Biol. 2003; 23: 160-167
        • Plump A.S.
        • Masucci-Magoulas L.
        • Bruce C.
        • et al.
        Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1105-1110
        • Hayek T.
        • Masucci-Magoulas L.
        • Jiang X.
        • et al.
        Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.
        J Clin Invest. 1995; 96: 2071-2074
        • Föger B.
        • Chase M.
        • Amar M.J.
        • et al.
        Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.
        J Biol Chem. 1999; 274: 36912-36920
        • Zhong S.B.
        • Sharp D.S.
        • Grove J.S.
        • et al.
        Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.
        J Clin Invest. 1996; 97: 2917-2923
        • de Grooth G.J.
        • Kuivenhoven J.A.
        • Stalenhoef A.F.
        • et al.
        Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose–response study.
        Circulation. 2002; 105: 2159-2165
        • Clark R.W.
        • Sutfin T.A.
        • Ruggeri R.B.
        • et al.
        Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
        Arterioscler Thromb Vasc Biol. 2004; 24: 490-497
        • Brousseau M.E.
        • Diffenderfer M.R.
        • Millar J.S.
        • et al.
        Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
        Arterioscler Thromb Vasc Biol. 2005; 25: 1057-1064
        • Yamashita S.
        • Hirano K.
        • Sakai N.
        • Matsuzawa Y.
        Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.
        Biochim Biophys Acta. 2000; 1529: 257-275
        • Paromov V.M.
        • Morton R.E.
        Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesteryl ester transfer protein (CETP).
        J Biol Chem. 2003; 278: 40859-40866
        • Morton R.E.
        • Zilversmit D.B.
        Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma.
        J Lipid Res. 1982; 23: 1058-1067
        • Morton R.E.
        Interaction of plasma-derived lipid transfer protein with macrophages in culture.
        J Lipid Res. 1988; 29: 1367-1377
        • Morton R.E.
        • Steinbrunner J.V.
        Concentration of neutral lipids in the phospholipid surface of substrate particles determines lipid transfer protein activity.
        J Lipid Res. 1990; 31: 1559-1567
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
        J Clin Invest. 1955; 34: 1345-1353
        • Fraenkal-Conrat H.
        Methods for investigating the essential groups for enzyme activity.
        Meth Enzymol. 1957; 4: 247-269
        • Pattnaik N.M.
        • Montes A.
        • Hughes L.B.
        • Zilversmit D.B.
        Cholesteryl ester exchange protein in human plasma: isolation and characterization.
        Biochim Biophys Acta. 1978; 530: 428-438
        • Morton R.E.
        • Zilversmit D.B.
        The separation of apolipoprotein D from cholesteryl ester transfer protein.
        Biochim Biophys Acta. 1981; 663: 350-355
        • Peterson G.L.
        A simplification of the protein assay method of Lowry et al. which is more generally applicable.
        Anal Biochem. 1977; 83: 346-356
        • Chen W.
        • Silver D.L.
        • Smith J.D.
        • Tall A.R.
        Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages.
        J Biol Chem. 2000; 275: 30794-30800
        • Stokke K.T.
        • Norum K.R.
        Determination of lecithin:cholesterol acyltransfer in human blood plasma.
        Scand J Clin Lab Invest. 1971; 27: 21-27
        • Skeggs J.W.
        • Morton R.E.
        LDL and HDL enriched in triglyceride promote abnormal cholesterol transport.
        J Lipid Res. 2002; 43: 1264-1274
        • Morton R.E.
        • Greene D.J.
        CETP and lipid transfer inhibitor protein are uniquely affected by the negative charge density of the lipid and protein domains of LDL.
        J Lipid Res. 2003; 44: 2287-2296
        • Swenson T.L.
        • Hesler C.B.
        • Brown M.L.
        • et al.
        Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope.
        J Biol Chem. 1989; 264: 14318-14326
        • Clark R.W.
        • Ruggeri R.B.
        • Cunningham D.
        • Bamberger M.J.
        Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action.
        J Lipid Res. 2006; 47: 537-552
        • Ishigami M.
        • Yamashita S.
        • Sakai N.
        • et al.
        Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency cannot protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins.
        J Biochem (Tokyo). 1994; 116: 257-262
        • Ohta T.
        • Nakamura R.
        • Takata K.
        • et al.
        Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency.
        J Lipid Res. 1995; 36: 696-704
        • Sakai N.
        • Yamashita S.
        • Hirano K.I.
        • et al.
        Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency.
        Eur J Clin Invest. 1995; 25: 332-339
        • Liu M.
        • Bagdade J.D.
        • Subbaiah P.V.
        Specificity of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species.
        J Lipid Res. 1995; 36: 1813-1824
        • Rudel L.L.
        • Parks J.S.
        • Sawyer J.K.
        Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects African green monkeys from coronary artery atherosclerosis.
        Arterioscler Thromb Vasc Biol. 1995; 15: 2101-2110
        • Hirano K.
        • Yamashita S.
        • Matsuzawa Y.
        Pros and cons of inhibiting cholesteryl ester transfer protein.
        Curr Opin Lipidol. 2000; 11: 589-596
        • Mann C.J.
        • Yen F.T.
        • Grant A.M.
        • Bihain B.E.
        Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.
        J Clin Invest. 1991; 88: 2059-2066
        • Morton R.E.
        Binding of plasma-derived lipid transfer protein to lipoprotein substrates: the role of binding in the lipid transfer process.
        J Biol Chem. 1985; 260: 12593-12599
        • Nishida H.I.
        • Arai H.
        • Nishida T.
        Cholesterol ester transfer mediated by lipid transfer protein as influenced by changes in the charge characteristics of plasma lipoproteins.
        J Biol Chem. 1993; 268: 16352-16360
        • Morton R.E.
        • Zilversmit D.B.
        A plasma inhibitor of triglyceride and cholesteryl ester transfer activities.
        J Biol Chem. 1981; 256: 11992-11995
        • Yen F.T.
        • Deckelbaum R.J.
        • Mann C.J.
        • et al.
        Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma.
        J Clin Invest. 1989; 83: 2018-2024
        • Fielding C.J.
        • Fielding P.E.
        Regulation of human plasma lecithin:cholesterol acyltransferase activity by lipoprotein acceptor cholesteryl ester content.
        J Biol Chem. 1981; 256: 2102-2104